UPDATE : Thursday, December 12, 2019
상단여백
‘There should be no Invossa fiasco again’ by Kim Yun-mi 2019-12-11 15:03
‘Lynparza raises value of precision medicine as anticancer treatment’ by Kim Yun-mi 2019-12-05 16:05
Regulator’s re-evaluation of cognitive enhancer to take time by Kim Yun-mi 2019-11-27 12:07
Roche’s flu treatment Xofluza wins approval by Kim Yun-mi 2019-11-26 16:08
Immunotherapies give hope for esophageal cancer patients by Kim Yun-mi 2019-11-26 15:37
라인
Drugmakers obliged to conduct impurity tests and report results by Kim Yun-mi 2019-11-25 16:09
Korea, Singapore to cooperate on GMP in pharmaceuticals by Kim Yun-mi 2019-11-25 14:49
‘Korea's vaccine industry needs to grow to secure self-sufficiency’ by Kim Yun-mi 2019-11-25 11:55
Regulator bans 13 nizatidine drugs over carcinogenic risk by Kim Yun-mi 2019-11-22 15:32
Regulator detects NDMA also in nizatidine drugs by Kim Yun-mi 2019-11-21 10:53
라인
‘Japan much advanced than Korea in ALK-positive NSCLC treatment’ by Kim Yun-mi 2019-11-20 16:16
Will Biogen be 1st to get FDA nod for Alzheimer’s drug? by Kim Yun-mi 2019-11-14 11:23
‘Generic drugs must indicate ingredient names on label’ by Kim Yun-mi 2019-11-13 15:51
Sanofi’s DPT vaccine in shortage in some parts of Korea by Kim Yun-mi 2019-11-11 15:27
Takeda’s labor turmoil goes to extremes amid rumored unit sell-off by Kim Yun-mi 2019-11-07 16:10
라인
AbbVie’s hepatitis C drug gets 8-week therapy regardless of cirrhosis by Kim Yun-mi 2019-11-06 16:00
Regulator to consider re-classifying choline alfoscerate as functional food by Kim Yun-mi 2019-11-06 13:54
Merck Korea hurries to close GM part despite union’s protest by Kim Yun-mi 2019-11-05 15:04
Takeda Korea fires union leader to worsen labor-management dispute by Kim Yun-mi 2019-11-04 15:03
Hanyang University Medical Center goes research-centered by Kim Yun-mi 2019-11-01 16:09
여백
여백
여백
Back to Top